Experimental nanoparticle drug enters human testing for aggressive leukemia
Disease control
Recruiting now
This is an early-stage study to test the safety of a new drug called Ceramide NanoLiposome (CNL) in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to find a safe dose for future studies. Participants receive th…
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC